5 Covid Related Stocks To Consider This Month

Biogen Inc. (NASDAQ: BNTX) is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company’s pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.

Oncotelic Therapeutics, Inc. (OTC: OTLC) is an artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-β RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients. OT-101 also has shown activity against SARS-CoV-2 and has completed a phase 2 trial against COVID-19 with data cleaning and datalock ongoing.

Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic also has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503). The Company also acquired PointR Data Inc. (“PointR”) in November 2019.

The company recently announced that it has submitted clinical study protocol to the US FDA for the initiation of a Phase 2 Trial (designated “M201”) for OT-101, the Company’s TGF-β inhibitor, in combination with Anti-PD-1 (Pembrolizumab/Keytruda®) as a treatment for patients with Malignant Pleural Mesothelioma (MPM).

M201: Phase 2 Trial of TGF-β Inhibition (OT-101) with Anti-PD-1 (Pembrolizumab) in Patients with Malignant Pleural Mesothelioma (MPM) Failing to Achieve or Maintain Response to Checkpoint Inhibition.

OT-101 is a first-in-class anti-TGF-β ribonucleic acid (“RNA”) therapeutic that has exhibited single agent activity in relapsed/refractory cancer patients in multiple clinical trials. OT-101 has also demonstrated activity against the SARS-CoV-2 virus, the virus that causes COVID-19, and is currently being evaluated in the Company’s C001 clinical trial against hospitalized severe COVID-19 patients. Both tumor cells and SARS-Cov-2 induce TGF-β as part of their immune evasion mechanism. Consequently, inhibiting TGF-β by OT-101 is expected to impact both cancer and COVID.

The OT-101 oncology program (“OT-101-ONC”) is designed to assess the impact of OT-101 across multiple cancer indications where local tumoral secretion of TGF-β suppressed the clinical activity of checkpoint inhibitors, CAR-T, and vaccine. The OT-101-ONC program has been moving forward steadily through strategic alliance with top pharmaceutical companies. Of note is the biomarker program spanning mesothelioma, glioblastoma, lung and colorectal cancers, where AI driven transcriptome analyses will be used to derive the predictive biomarker for TGF-β therapeutics such as OT-101.

Fulgent Genetics, Inc. (NASDAQ: FLGT), together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home COVID-19 test capabilities; and has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

NRX Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company’s pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depression in patients with acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Contents published in this website contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FastMoneyLeaks undertakes no obligation to update such statements. FastMoneyLeaks was not compensated by companies mentioned in this article. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment. Advertisements received by you are not a solicitation or recommendation to buy securities of the advertised company.

 

Recent

FBC Holding Inc. (OTC: FCBD) shares On Watch After a Host of Positive News From The Company Boosted Investors Sentiment

Earlier this year, things were looking up for clothing retailers. Month after month, specialty apparel and department stores this year have posted healthy gains, as...

Theses four attractive companies could deliver massive gains over the next few months: FBCD, CZNI, VRUS, PLPL

Penny stocks are without a doubt one of the most rewarding ways to build wealth over a short period of time. The art of...

As many investors are getting ready to ride the next green wave, CBDL,ERBB and CBDD should be on top of everyone’s watchlist

Early investors in cannabis stocks generated unbelievable returns from 2017 to 2020. The legalization of the green medical and recreational use unleashed a multi-billion-dollar...

SHEIN Launches evoluSHEIN, New Clothing Line, FBC Holding, Inc. (FBCD) through its wholly owned subsidiary, Formrunner Apparel Inc. introduce the addition of its clothing...

SHEIN, an online retailer of fashion, beauty and lifestyle products, recently announced the launch of evoluSHEIN, a purpose-driven collection available to SHEIN customers around...

A host of companies are seeking to make the metaverse happen: AllStar Health Brands (ALST), Nvidia (NVDA), Matterport (MTTR), Unity Software Inc. (U)

Regardless of how markets perform next week or next month, there are some areas that should be very profitable over the long term. And...

3 CBD Skin/Beauty Related Stocks To Consider: Sentient Brands Holdings Inc. , Ulta Beauty, Inc., CV Sciences, Inc.

Analysts at Cowen note that CBD products "are now available through increasingly diverse retail channels, including Amazon, Sephora and Neiman Marcus." They peg the...

3 Stocks To Consider in the Multi Trillion Dollar Agriculture Industry: SNRG, SMG, NTR

Agriculture is a life-sustaining operation, and there are numerous ways for investors to own a piece of the action. Investors can choose among companies...

With strong management and multi-tiered growth strategies, shares of these 5 boat companies should be considered this year

Yacht Market size surpassed USD 12 billion in 2020 and is anticipated to grow at over 4.5% CAGR from 2021 to 2027. Rising demand...

3 Promising Penny Stocks To Consider This Year

Penny stocks are without a doubt one of the most rewarding ways to build wealth over a short period of time. The art of...

4 Stocks To Watch As The pet industry has been experiencing explosive growth over the last 2 years: CSOC, WOOF, FRPT, CENT

Interest in the pet industry has surged during the COVID-19 pandemic, but there are a lot of reasons to invest in pet stocks. According...

As Oil prices are poised to push higher in the short term horizon, these three stocks look well-positioned to outperform

The global economy is reopening,  Airplanes, in the U.S. and all over the world, are almost fully operating again, traffic is now back. The reopening...

Bitcoin’s Bounce Is fueling a rally in crypto-related stocks: Silvergate Capital, Net Savings Link, Inc., NextMart, Inc. On Watch

COVID-19 helped accelerate a number of digital reforms in companies large and small. Professional investors, billionaires and even publicly traded companies have maintained a keen...

4 Stocks To Consider Buying As Gold Shows the Potential to Set New Records This Year

In today’s environment, we’re at the point where investors should be approaching a significant gold position. First, because of the uncertainty in markets. However, also...